Quality of life results in the UK TACT2 Trial of accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer: a multicentre, phase 3, open-label, randomised, controlled trial (CRUK/05/19)

Thumbnail Image

Files

Quality of life results in the UK TACT2 Trial of accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer.pdf (4.63 MB)

Embargo End Date

ICR Authors

Bliss, Judith

Authors

Bliss, J

Document Type

Journal Article

Date

Date Accepted

2023-09-12

Abstract

Citation

The Lancet Oncology,

DOI

URI

https://repository.icr.ac.uk/handle/internal/6064

Rights

https://creativecommons.org/licenses/by-nc-nd/4.0/

Source Title

The Lancet Oncology

Publisher

Elsevier

ISSN

1213-9432

eISSN

Collections

Clinical Studies

Research Team

Clin Trials & Stats Unit

Notes